Investors

Marseille, March 18, 2021 (GLOBE NEWSWIRE) -- Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphoma Company’s first NK cell engager selected by Sanofi as drug candidate

Marseille, March 16, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Thursday, March 18, 2021 at 2 p.m. CET / 9 a.m.

Marseille, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) General Regulation, Innate Pharma SA (the “Company” - Euronext Paris: